Outset Medical (Nasdaq: OM) announced today that the FDA says it addressed all issues cited in a 2023 warning letter.

To provide medical professionals (RN, MD, Pharmacist) with the knowledge and understanding for decision making for the effective utilization of Continuous Renal Replacement Therapy (CRRT) and to allow ...

The work group aimed to make recommendations to clarify the processes for prescribing and preparing CRRT solutions based on the medication error data collected by the ...

A recent meta-analysis concluded that continuous renal replacement therapy (CRRT) is not superior to intermittent renal replacement therapy (IRRT) in terms of hemodynamic control, renal recovery ...

The abstract of the RENAL Replacement Therapy study concludes that in critically ill patients with acute kidney injury, treatment with higher-intensity continuous renal replacement therapy did not ...

We conducted a single-center observational study of pediatric patients undergoing CRRT during the period of July 2007 through July 2010 at a tertiary care children's hospital. This study was ...

The trial is assessing the efficacy and safety of the company's selective cytopheretic device (SCD) in conjunction with continuous renal replacement therapy (CRRT). The trial aims to enrol 200 adult ...

The global continuous renal replacement therapy market is set for significant expansion, with projections indicating a surge ...

The paediatric CRRT team of Jiangsu Provincial People’s Hospital raced to Zhenjiang on 2 February hearing of the baby’s ...

Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week The FDA agreed to two additional protocol changes ...